RVI is a specific immunomodulator agent (IMA) with subvaccination levels of an inactivated rubeola virus that acts to modify the immune and inflammatory responses to alleviate Chronic Myofascial Inflammation (chronic muscle soreness) and its associated problems in the equine.
Click here for our Vaccine Shipping Schedule.
RUBEOLA VIRUS IMMUNOMODULATOR
U.S. Vet. Lic. No.: 385
Active Ingredient(s): An inactivated rubeola virus combined with histamine phosphate in physiological saline. Contains phenol as a preservative. Each 2 mL dose contains 0.1 mcg of neomycin.
Indications: RVI acts to modify the immune and inflammatory responses to alleviate chronic myofascial inflammation (myositis) and its associated problems in the equine.
Dosage and Administration: Inject 2 mL subcutaneously in the neck once a day regardless of weight or age for three (3) to six (6) days or until the desired clinical condition is observed. In severe cases, a daily injection may be required until the horse recovers. Maintenance doses and frequency will depend upon the individual animal but may vary from one (1) dose every other day to one (1) dose a week or even every two (2) weeks. Care should be exercised to ensure that the injection is delivered subcutaneously.
Precaution(s): Store at 35°-45°F (2°-7°C). Protect from freezing.
Caution(s): Rare transient local reactions may occur at the injection site but should subside within 24 hours. For veterinary use only.
Warning(s): Not for use in horses intended for food.
Discussion: T-lymphocytes, including suppressor T-cells, significantly modulate the immune response. Unfortunately these cells are very sensitive to insult, whether from stress, dietary changes, infection, or environmental toxins. These suppressor T-cells function by controlling B-cells (the antibody producers), cytotoxic cells, and helper T-cells from over-responding to insults. Unless controlled, this over response could result in an immune response to auto or self antigens. Evidence indicates an auto immune component to chronic myofascial inflammation and myositis. Studies reflect a decrease in suppressor T-cell function, although not necessarily a decrease in the absolute number of T-cells. RVI acts by specifically modulating suppressor T-cell function in a controlled fashion to allow re-establishment of the normal balance between various subpopulations of T- and B-lymphocytes. This will aid in the healing process leading to the decrease or elimination of myofascial inflammation in the affected animals.
References: Available upon request.
* U.S. Patent No. 4,705,685
Presentation: 12 x 12 mL six dose vials.NAC No.: 1404001.0